Editor's Note: The 10th West China Urologic Oncology Tianfu Academic Conference was held in Chengdu from November 5 to 7, 2026. As antibody-drug conjugates (ADCs) enter different stages of urothelial carcinoma treatment, drug selection, treatment timing, and sequencing strategies have become new clinical challenges. On this occasion, Oncology Frontier – UroStream invited Professor Liangyou Gu of the Chinese PLA General Hospital to share insights into the key recommendations of the Expert Guidance on the Clinical Application of ADCs in Advanced Urothelial Carcinoma, focusing on first-line treatment selection, later-line sequencing, and safety management.

01

Oncology Frontier – UroStream: As ADCs continue to enter different stages of urothelial carcinoma treatment, clinicians face new questions regarding drug selection, treatment timing, and sequencing strategies. Which key clinical needs does this expert guidance address, and what recommendations does it offer for clinical practice?

Professor Liangyou Gu: In the treatment of urothelial carcinoma, particularly advanced urothelial carcinoma, we have essentially entered the ADC era. An increasing range of drugs is becoming accessible in clinical practice, both domestically and internationally, and ADCs have become a mainstream treatment approach. With these drugs now more widely available, clinicians need preliminary guidance and recommendations to ensure that they are used in a more structured and standardized manner. Therefore, consensus statements and expert guidance of this kind can provide genuinely practical assistance.

The recommendations provide guidance and reference points across several key areas.

First, the selection and timing of first-line regimens. Based on currently available Phase III trial data, the recommendations support first-line combinations such as enfortumab vedotin (EV) plus pembrolizumab (Keytruda), or disitamab vedotin (RC48) plus toripalimab. Regarding treatment timing, the recommendations favor active use of these regimens in the first-line setting to achieve longer-lasting tumor control.

Second, the selection of patient populations likely to benefit. EV targets Nectin-4, and the consensus clearly states that routine testing for Nectin-4 expression is not required, as this target is highly and relatively uniformly expressed in most patients. Expression patterns vary among different targets. Further studies are needed to clarify the relationship between the location of expression, such as cytoplasmic versus membranous expression, and treatment efficacy. Whether more detailed expression testing, as performed in some other cancer types, will be necessary remains an open question. Ultimately, the key consideration is whether such testing can genuinely help guide clinical decisions.

Third, adequate treatment duration, full dosing, and standardized management. The favorable efficacy achieved in Phase III trials is often not fully reproduced in real-world practice, largely because patients do not receive sufficient doses or complete treatment courses. A substantial body of previous research, including Phase III and exploratory studies, has already provided a relatively clear understanding of dose selection. Clinicians should therefore aim to deliver adequate doses and treatment duration in accordance with this evidence.

Another challenge is the complexity of patient management. In registration trials, investigators, clinical research coordinators (CRCs), and clinical research associates (CRAs) help ensure timely communication with patients and appropriate management. In routine clinical practice, however, clinicians face heavy workloads, and patient communication and management may not be as intensive as in clinical trials. Therefore, high-risk patients require more timely communication, standardized management of adverse reactions, and appropriate dose adjustments.

In addition, an increasing amount of evidence and more recommendations are now available for the perioperative setting. Evidence is emerging across the treatment continuum, from later-line to earlier-line therapy, including neoadjuvant and postoperative adjuvant treatment of urothelial carcinoma. These findings can provide clinicians with additional guidance and reference points.

02

Oncology Frontier – UroStream: For patients with advanced urothelial carcinoma whose disease has progressed following first-line ADC treatment, what are the most important factors clinicians should consider when making subsequent treatment decisions?

Professor Liangyou Gu: ADC monotherapy and ADC combined with immunotherapy are both important tools in the treatment of advanced urothelial carcinoma. However, treatment “failure” needs to be considered in a more nuanced way.

If a patient experiences disease progression on ADC monotherapy, subsequent options may include immunotherapy, another ADC, or conventional chemotherapy.

When an ADC is combined with immunotherapy, treatment may also be adjusted during the course of therapy. One possibility involves modifying the dose or treatment schedule. After approximately six months of ADC plus immunotherapy, some patients develop toxicities that become difficult to tolerate. In such cases, the ADC may be discontinued while immunotherapy is continued. This approach can still provide prolonged disease control and a favorable long-tail effect.

After the combination regimen ultimately fails, several factors need to be considered when selecting subsequent treatment. First, if the ADC was discontinued because of toxicity and the patient subsequently experiences disease progression while receiving maintenance immunotherapy alone, resuming the previous ADC may be an option. Second, conventional chemotherapy remains an option alongside ADCs and immunotherapy. Third, as more drugs become available, switching between ADCs with different targets or payloads is becoming increasingly feasible. In addition to HER2-targeted and Nectin-4-targeted ADCs, TROP2-targeted ADCs and HER3 bispecific ADCs are also available.

Based on current experience, switching to EV after failure of an HER2-targeted ADC carrying an MMAE payload, such as RC48, does not appear to produce particularly favorable outcomes. Whether switching to an ADC with a different target and a different payload would be more effective remains to be established through further data. Given the scope of the current consensus and the evidence currently available, this issue is not discussed in great detail. As more ADCs become accessible, determining how best to sequence these agents will be an important focus for the future.

03

Oncology Frontier – UroStream: Although ADCs offer meaningful efficacy benefits, they also have characteristic toxicity profiles. Comprehensive safety management throughout treatment directly affects patients’ ability to continue therapy. What key management measures does the guidance recommend for peripheral neuropathy, skin toxicity, and ocular toxicity? How should clinicians determine the appropriate timing of monitoring, intervention, dose reduction, or treatment discontinuation?

Professor Liangyou Gu: With access to more and better treatment options, patients can indeed achieve substantial benefits. However, how well these tools are used is equally important. Adequate treatment duration and dosing can produce favorable efficacy, but once adverse reactions occur, early monitoring and management are essential if patients are to achieve long-term survival.

The toxicity profiles of different drugs are primarily determined by two factors: the target and the payload. The expression levels of a target vary across different tissues, and this is an important factor to consider. The payload, essentially, exerts its cytotoxic effect through a chemotherapy-like mechanism, so its associated toxicities also require attention. Some drugs are more likely to cause neurotoxicity, while others are primarily associated with myelosuppression. These profiles differ from one drug to another. In addition, patients’ baseline conditions and comorbidities must also be taken into account.

On this basis, patients should undergo monitoring during every treatment cycle, with adverse events promptly graded and managed. When Grade 2 or 3 adverse events occur, treatment interruption and appropriate intervention are often required. Treatment can then be considered for resumption once the toxicity has improved to Grade 1 or lower.

When drugs are used in combination, attribution of adverse events must also be considered. ADCs are commonly combined with immunotherapy in clinical practice. These combinations may produce synergistic antitumor effects, but they may also increase the risk of adverse events. Clinicians need to determine which drug is primarily responsible for a particular adverse event, as management approaches may differ. Once the adverse event has adequately resolved, the appropriate approach to resuming the two drugs can be reassessed.

Overall, these drugs have demonstrated clear efficacy, but their management requires the experience of specialists as well as greater multidisciplinary collaboration. Systemic treatment may affect multiple organs. Through multidisciplinary team (MDT) discussions and communication, adverse events can be managed more effectively, ultimately helping patients achieve long-term disease control.